Overview

A Randomized, Multicenter Pragmatic Trial Comparing Bone Pain From a Single Dose of Pegfilgrastim to 5 Doses of Daily Filgrastim in Breast Cancer Patients Receiving Neoadjuvant/Adjuvant Chemotherapy

Status:
Recruiting

Trial end date:
2023-12-01

Target enrollment:

Participant gender:

Summary

REaCT-5G will compare bone pain from a single dose of Pegfilgrastim to 5 doses of daily filgrastim in breast cancer patients receiving neoadjuvant/adjuvant chemotherapy.

Phase:

Phase 4

Details

Lead Sponsor:

Ottawa Hospital Research Institute

Treatments:

Lenograstim